International Deals

My time has been spent in ?Europe.? In the last two days, I have been to Italy four times, London and France each twice and made brief stops in Germany and Switzerland. The series of meetings that I have had with European companies has caused me to come to the conclusion that companies in that region are undervalued, undermanaged, underappreciated and unhappy with the lack of availabe capital. The companies are therefore looking to gain additional investor support from US venture capitalists.

By | January 12, 2006

My time has been spent in ?Europe.? In the last two days, I have been to Italy four times, London and France each twice and made brief stops in Germany and Switzerland. The series of meetings that I have had with European companies has caused me to come to the conclusion that companies in that region are undervalued, undermanaged, underappreciated and unhappy with the lack of availabe capital. The companies are therefore looking to gain additional investor support from US venture capitalists. At the same time, European venture capitalists are expressing concern with the inability to find local IPO exits for many of their companies and are looking to the US to find better investees. Anonymous Quote of the Day: ?A good biotech CEO is like a bullfighter: he possesses agility, grace, courage to stare danger in the face and only the remote prospect of being paid well if he survives.?

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech